Scientific article
OA Policy
English

Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

Published inRheumatology International, vol. 40, no. 5, p. 747-755
Publication date2020
Abstract

Assessment of individual therapeutic responses provides valuable information concerning treatment benefits in individual patients. We evaluated individual therapeutic responses as determined by the Disease Activity Score-28 joints critical difference for improvement (DAS28-dcrit) in rheumatoid arthritis (RA) patients treated with intravenous tocilizumab or comparator anti-tumor necrosis factor (TNF) agents. The previously published DAS28-dcrit value [DAS28 decrease (improvement) ≥ 1.8] was retrospectively applied to data from two studies of tocilizumab in RA, the 52-week ACT-iON observational study and the 24-week ADACTA randomized study. Data were compared within (not between) studies. DAS28 was calculated with erythrocyte sedimentation rate as the inflammatory marker. Stability of DAS28-dcrit responses and European League Against Rheumatism (EULAR) good responses was determined by evaluating repeated responses at subsequent timepoints. A logistic regression model was used to calculate p values for differences in response rates between active agents. Patient-reported outcomes (PROs; pain, global health, function, and fatigue) in DAS28-dcrit responder versus non-responder groups were compared with an ANCOVA model. DAS28-dcrit individual response rates were 78.2% in tocilizumab-treated patients and 58.2% in anti-TNF-treated patients at week 52 in the ACT-ion study (p = 0.0001) and 90.1% versus 59.1% at week 24 in the ADACTA study (p < 0.0001). DAS28-dcrit responses showed greater stability over time (up to 52 weeks) than EULAR good responses. For both active treatments, DAS28-dcrit responses were associated with statistically significant improvements in mean PRO values compared with non-responders. The DAS28-dcrit response criterion provides robust assessments of individual responses to RA therapy and may be useful for discriminating between active agents in clinical studies and guiding treat-to-target decisions in daily practice.

Keywords
  • Antibodies
  • Monoclonal
  • Humanized/administration & dosage
  • Antirheumatic Agents/administration & dosage
  • Arthritis
  • Rheumatoid/drug therapy
  • Blood Sedimentation/drug effects
  • Humans
  • Observational Studies as Topic
  • Patient Reported Outcome Measures
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors/administration & dosage
Citation (ISO format)
KOEHM, Michaela et al. Individual therapeutic DAS28-d crit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies. In: Rheumatology International, 2020, vol. 40, n° 5, p. 747–755. doi: 10.1007/s00296-020-04514-7
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
Journal ISSN0172-8172
192views
51downloads

Technical informations

Creation06/09/2021 15:53:00
First validation06/09/2021 15:53:00
Update time24/01/2025 14:20:51
Status update24/01/2025 14:20:51
Last indexation24/01/2025 14:29:31
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack